Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) recently reported 24-week Phase 3 trial results showing sustained disease control for adults with moderate atopic dermatitis treated with Opzelura cream, as the company …
Incyte Reports Extended Opzelura Eczema Trial Results Read More WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) granted equity inducement awards to newly appointed Executive Vice President and Chief Financial Officer Suketu Upadhyay as part of his employment agreement with …
Incyte Grants Equity Awards to New CFO Suketu Upadhyay Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) recently received U.S. Food and Drug Administration approval for Jakafi XR, a once-daily extended-release version of ruxolitinib, giving patients with several chronic blood disorders …
FDA Approves Once-Daily Jakafi XR for Blood Disorders Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will present at two healthcare investor conferences in May as biotechnology companies continue using industry events to update investors on pipeline development, commercialization efforts, …
Incyte to Present Pipeline Strategy at May Investor Conferences Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) appointed Suketu Upadhyay as executive vice president and chief financial officer effective May 4, 2026, the company announced.
Incyte Appoints Suketu Upadhyay as Chief Financial Officer Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported first-quarter 2026 revenue of $1.27 billion and total net sales of $1.10 billion, increases of 21% and 20%, respectively, from the same period …
Incyte Reports Q1 Revenue Growth as Pipeline Advances Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will present full results from a Phase 3 study of tafasitamab for first-line diffuse large B-cell lymphoma at the American Society of Clinical Oncology …
Incyte to Present Phase 3 Tafasitamab Data at ASCO Meeting Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will release its first-quarter 2026 financial results at 7:00 a.m. ET on Tuesday, April 28, followed by a conference call at 8:00 a.m. ET.
Incyte to Report Q1 Results on April 28 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported 54-week Phase III data showing its experimental drug povorcitinib reduced disease activity in patients with moderate to severe hidradenitis suppurativa, the company announced …
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced executive leadership changes, including the appointment of Pablo J. Cagnoni, M.D., as president and global head of research and development, as the company …
Incyte Names Cagnoni President, Announces Leadership Changes Read More